top of page
ASX:HPC
Hydration Pharmaceuticals Co Ltd Fully Paid Ord. Shrs
Investment Summary
The fund managers believe that Hydration Pharmaceuticals Co Ltd is poised for significant growth. In their opinion, the updates on US operations indicate strong performance, particularly with the Liver Detox product, which has shown incredible growth. They emphasize that ongoing focus on cost management is contributing to consistent monthly increases in EBITDA. This trend reinforces their belief that HPC is on track to achieve a sustainable level of profitability in its US operations within the next 12 months, making it an attractive investment opportunity.
Commentary From The Managers
Saville Capital
30 Nov 2024
$0.02
- Saville Capital provides an update on their investment thesis regarding Hydration Pharmaceuticals Co Ltd.
- HPC reported impressive growth in their Liver Detox product.
- There is a strong focus on cost management, which is supporting financial performance.
- This ongoing management effort is linked to monthly increases in EBITDA.
- There is confidence in achieving sustainable profitability for US operations in the next 12 months.
- Saville Capital continues to monitor these developments closely.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
bottom of page